CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses
Background To date, T cells redirected with CD19-specific chimeric antigen receptors (CAR) have gained impressive success in B-cell malignancies. However, treatment failures are common and the occurrence of severe toxicities, such as cytokine release syndrome (CRS), still limits the full exploitatio...
Saved in:
Main Authors: | Alice Bergamini, Barbara Camisa, Attilio Bondanza, Fabio Ciceri, Chiara Bonini, Monica Casucci, Beatrice Greco, Camilla Bove, Silvia Arcangeli, Laura Falcone, Rita El Khoury, Anna De Lucia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/1/e005878.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia
by: Haotian Ma, et al.
Published: (2024-11-01) -
Large-scale manufacturing and characterization of CMV-CD19CAR T cells
by: Stephen J Forman, et al.
Published: (2022-01-01) -
Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia
by: Rui Zhang, et al.
Published: (2025-02-01) -
CD3+CD8+CD28− T Lymphocytes in Patients with Lupus Nephritis
by: Marcelina Żabińska, et al.
Published: (2016-01-01) -
Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells
by: Kohei Mitsuno, et al.
Published: (2025-02-01)